Indrayani Biotech delays FY26 audited results meeting

What the company disclosed

Indrayani Biotech Limited has deferred its Board meeting that was meant to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The company attributed the delay to the consolidation of subsidiary results and the time required to complete audit processes. It said the Board meeting will be held at a later date because accounts are still being finalised.

The company also reiterated that the trading window for designated persons remains closed. The window will reopen only 48 hours after the audited financial results for the period ended March 31, 2026 are declared.

Why the timing matters under SEBI rules

Indrayani Biotech stated it was required to submit standalone and consolidated results by May 30, 2026. This requirement was referenced under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

A delay in approving audited results can become a key compliance and disclosure issue for listed companies because audited annual numbers are widely used by investors and lenders to assess profitability, balance sheet strength, and cash flow trends. In this case, the company has linked the delay directly to consolidation and audit completion, rather than business operations.

Trading window closure and what it means

The company said the trading window for designated persons remains closed until 48 hours after the results are declared. Such closures are typically used to limit trading by insiders when price-sensitive information is pending.

For investors tracking the stock, the trading-window detail is a process disclosure rather than a statement on performance. However, it signals that audited numbers have not yet been placed before the Board for approval and publication.

A similar pattern seen in FY25

Indrayani Biotech has previously communicated audit and consolidation related timing changes. In a BSE disclosure dated 09/06/2025, the company said its Board meeting to approve audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2025 needed more time. The meeting that was planned for 9 June 2025 was adjourned to 12 June 2025.

In that disclosure, the company also cited consolidation of subsidiary results along with completion of internal and external audit processes as taking longer than estimated. The FY26 delay uses similar reasoning, indicating that consolidation and audit timelines continue to be an important operational dependency for the company’s reporting schedule.

Recent earnings snapshot: Q3 FY26 profitability pressure

The provided earnings note states that Indrayani Biotech Ltd’s net profit fell 75% year-on-year to ₹0.06 crore in Q3 2025-2026. On a quarterly basis, the company recorded an 85% fall in net profit compared with the previous three-month period.

The same data set also describes Indrayani Biotech as a company in the food sector. While audited FY26 numbers are pending, the sharp decline in quarterly profit adds context to why investors may pay close attention to the audited annual outcome and any audit-related qualifications or explanatory notes.

Operating margin and profit trend points from the data tables

The quarterly table shared shows operating profit margin volatility across periods from Sep 2023 to Dec 2025, including a negative operating profit margin of -5.7% in Mar 2025, followed by positive margins in subsequent quarters. The annual table from Mar 2020 to Mar 2025 also shows large swings in operating profit margin, including -42.96% in Mar 2021 and 14.11% in Mar 2024, before falling to 4.81% in Mar 2025.

The tables also show interest costs rising over the years listed, with interest at 11.76 in Mar 2025 compared with 9.88 in Mar 2024 (units were not specified in the provided table). Investors typically track such movement alongside operating profitability because higher finance costs can reduce net profit even when operating performance improves.

FY2023-24 annual report numbers: income and profit

In its annual report narrative for the year ended March 31, 2024, the company reported consolidated income and standalone income figures, along with profit after tax and year-on-year changes.

It said total consolidated income for FY2023-24 was ₹167.44 crore (converted from ₹16,744.06 lakh), an increase of ₹0.03 crore (converted from ₹2.61 lakh) or 0.15% over the previous year. Consolidated net profit after tax for FY2023-24 was ₹10.42 crore (from ₹1,042.25 lakh), down 14.46% versus ₹11.93 crore (from ₹1,193.07 lakh) in the previous year.

The annual report also stated total standalone income for FY2023-24 was ₹65.94 crore (from ₹6,594.22 lakh), a decrease of ₹9.18 crore (from ₹918.01 lakh) or 12% over the previous year. Standalone net profit after tax for FY2023-24 was ₹1.46 crore (from ₹145.74 lakh), down 71% versus the previous year (the previous-year standalone profit figure was not fully visible in the provided text).

The report also noted that there had been no frauds reported by the auditors pursuant to section 143(12) of the Companies Act, 2013.

Market snapshot from the provided data

The stock data line provided shows ₹7.860 and a +4.80% move. It also shows -9.86% and -30.50%, though the time periods for these returns were not specified in the text.

Because the FY26 audited results are delayed, trading and valuation discussions can remain sensitive to news flow on the new Board meeting date and publication of the audited statements.

Key facts table

Financial highlights table (FY2023-24)

Company contact details (as listed)

The provided text includes a Chennai address: Block 1, Module No.33, 3rd Floor, SIDCO Electronic Complex, Thiru-vi-ka Industrial Estate, Chennai (Madras), Tamil Nadu, 600032, with telephone 044-22502146 and email info@indrayani.com and website http://www.indrayani.com.

It also lists a Pune location: 1133/5 F C Road, Opp Police Grounds, Pune, Maharashtra, 411016, and mentions emails info@indrayani.com and indrayanichennai@gmail.com, along with phone 91-20-25662021.

What investors will watch next

The immediate next trigger is the revised date for the Board meeting to approve and declare the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Investors will also watch for the publication of the audited statements and any accompanying auditor observations, given that the company has cited audit completion as a reason for the delay.

Until the audited results are declared, the trading window for designated persons will remain shut and is scheduled to reopen 48 hours after the declaration, as disclosed by the company.